Case reports of juvenile GM1 gangliosidosisis type II caused by mutation in GLB1 gene

Parvaneh Karimzadeh, Samaneh Naderi, Farzaneh Modarresi, Hassan Dastsooz, Hamid Nemati, Tayebeh Farokhashtiani, Bibi Shahin Shamsian, Soroor Inaloo, Mohammad Ali Faghihi, Parvaneh Karimzadeh, Samaneh Naderi, Farzaneh Modarresi, Hassan Dastsooz, Hamid Nemati, Tayebeh Farokhashtiani, Bibi Shahin Shamsian, Soroor Inaloo, Mohammad Ali Faghihi

Abstract

Background: Type II or juvenile GM1-gangliosidosis is an autosomal recessive lysosomal storage disorder, which is clinically distinct from infantile form of the disease by the lack of characteristic cherry-red spot and hepatosplenomegaly. The disease is characterized by slowly progressive neurodegeneration and mild skeletal changes. Due to the later age of onset and uncharacteristic presentation, diagnosis is frequently puzzled with other ataxic and purely neurological disorders. Up to now, 3-4 types of GM1-gangliosidosis have been reported and among them type I is the most common phenotype with the age of onset around 6 months. Various forms of GM1-gangliosidosis are caused by GLB1 gene mutations but severity of the disease and age of onset are directly related to the position and the nature of deleterious mutations. However, due to its unique genetic cause and overlapping clinical features, some researchers believe that GM1 gangliosidosis represents an overlapped disease spectrum instead of four distinct types.

Case presentation: Here, we report a less frequent type of autosomal recessive GM1 gangliosidosis with perplexing clinical presentation in three families in the southwest part of Iran, who are unrelated but all from "Lurs" ethnic background. To identify disease-causing mutations, Whole Exome Sequencing (WES) utilizing next generation sequencing was performed. Four patients from three families were investigated with the age of onset around 3 years old. Clinical presentations were ataxia, gate disturbances and dystonia leading to wheelchair-dependent disability, regression of intellectual abilities, and general developmental regression. They all were born in consanguineous families with no previous documented similar disease in their parents. A homozygote missense mutation in GLB1 gene (c. 601 G > A, p.R201C) was found in all patients. Using Sanger sequencing this identified mutation was confirmed in the proband, their parents, grandparents, and extended family members, confirming its autosomal recessive pattern of inheritance.

Conclusions: Our study identified a rare pathogenic missense mutation in GLB1 gene in patients with complex neurodevelopmental findings, which can extend the list of differential diagnoses for childhood ataxia in Iranian patients.

Keywords: Case report; GLB1; GM1 gangliosidosis.

Figures

Fig. 1
Fig. 1
MRI report of patient I. a mild abnormal signal changes in periventricular white matter, b mild abnormal signal changes in periventricular white matter in T1 sequence
Fig. 2
Fig. 2
MRI image of Patient II. It indicates mild cerebellar atrophy in an axial Image of brain MRI
Fig. 3
Fig. 3
Pedigree and sanger sequencing details of Family I. Using Sanger sequencing, the inheritance mode of autosomal recessive was confirmed in this family based on identified heterozygote mutation in parents and homozygote in the proband. Sanger sequencing was performed on other patients, parents and their extended family members (data not shown)

References

    1. Sanchez-Fernandez EM, Garcia Fernandez JM, Mellet CO. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem Commun (Camb) 2016;52(32):5497–515. doi: 10.1039/C6CC01564F.
    1. Kannebley JS, Silveira-Moriyama L, Bastos LO, Steiner CE. Clinical Findings and Natural History in Ten Unrelated Families with Juvenile and Adult GM1 Gangliosidosis. JIMD Rep. 2015;24:115–22. doi: 10.1007/8904_2015_451.
    1. Sandhoff K, Harzer K. Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. J Neurosci. 2013;33(25):10195–208. doi: 10.1523/JNEUROSCI.0822-13.2013.
    1. Jeyakumar M, Thomas R, Elliot‐Smith E, Smith D, Van Der Spoel A, d’Azzo A, Perry VH, Butters T, Dwek R, Platt F. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 2003;126(4):974–87. doi: 10.1093/brain/awg089.
    1. Armstrong-Javors A, Chu CJ. Child neurology: Exaggerated dermal melanocytosis in a hypotonic infant: a harbinger of GM1 gangliosidosis. Neurology. 2014;83(17):e166–8. doi: 10.1212/WNL.0000000000000912.
    1. Callahan JW. Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure–function studies of lysosomal β-galactosidase and the non-lysosomal β-galactosidase-like protein. Biochim Biophys Acta (BBA) - Mol Basis Dis. 1999;1455(2):85–103. doi: 10.1016/S0925-4439(99)00075-7.
    1. Regier DS, Kwon HJ, Johnston J, Golas G, Yang S, Wiggs E, Latour Y, Thomas S, Portner C, Adams D, et al. MRI/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis. Am J Med Genet A. 2016;170(3):634–44. doi: 10.1002/ajmg.a.37468.
    1. Giugliani R, Dutra JC, Pereira MLS, Rotta N, de Drachler ML, Ohlweiller L, de Pina Neto JM, Pinheiro CE, Breda DJ. GM1 gangliosidosis: clinical and laboratory findings in eight families. Hum Genet. 1985;70(4):347–54. doi: 10.1007/BF00295376.
    1. Wolfe LS, Senior RG, Kin NNY. The structures of oligosaccharides accumulating in the liver of GM1-gangliosidosis, type I. J Biol Chem. 1974;249(6):1828–38.
    1. Suzuki Y, Oshima A. A beta-galactosidase gene mutation identified in both Morquio B disease and infantile GM1 gangliosidosis. Hum Genet. 1993;91(4):407. doi: 10.1007/BF00217370.
    1. Wenger DA, Goodman SI, Myers GG. Letter: Beta-galactosidase deficiency in young adults. Lancet. 1974;2(7892):1319–20. doi: 10.1016/S0140-6736(74)90173-1.
    1. Suzuki Y, Nakamura N, Fukuoka K, Shimada Y, Uono M. beta-Galactosidase deficiency in juvenile and adult patients. Report of six Japanese cases and review of literature. Hum Genet. 1977;36(2):219–29. doi: 10.1007/BF00273261.
    1. Quakenbush A. Analysis of the Ovine NEU1 Gene in a Unique Model of GM1 Gangliosidosis. 2015.
    1. Caciotti A, Bardelli T, Cunningham J, D’Azzo A, Zammarchi E, Morrone A. Modulating action of the new polymorphism L436F detected in the GLB1 gene of a type-II GM1 gangliosidosis patient. Hum Genet. 2003;113(1):44–50.
    1. Brunetti-Pierri N, Scaglia F. GM 1 gangliosidosis: Review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008;94(4):391–6. doi: 10.1016/j.ymgme.2008.04.012.
    1. Okada S, O’Brien JS. Generalized gangliosidosis: beta-galactosidase deficiency. Science. 1968;160(3831):1002–4. doi: 10.1126/science.160.3831.1002.
    1. Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics. 2011;5(3):1. doi: 10.1186/1479-7364-5-3-156.
    1. Yoshida K, Oshima A, Shimmoto M, Fukuhara Y, Sakuraba H, Yanagisawa N, Suzuki Y. Human beta-galactosidase gene mutations in GM1-gangliosidosis: a common mutation among Japanese adult/chronic cases. Am J Hum Genet. 1991;49(2):435–42.
    1. Acosta W, Martin R, Radin DN, Cramer CL. High-throughput imaging method for direct assessment of GM1 ganglioside levels in mammalian cells. Data Brief. 2016;6:1016–22. doi: 10.1016/j.dib.2016.01.027.
    1. Georgiou T, Stylianidou G, Anastasiadou V, Caciotti A, Campos Y, Zammarchi E, Morrone A, D’azzo A, Drousiotou A. The Arg482His mutation in the β-galactosidase gene is responsible for a high frequency of GM1 gangliosidosis carriers in a Cypriot village. Genet Test. 2005;9(2):126–32. doi: 10.1089/gte.2005.9.126.

Source: PubMed

3
Prenumerera